British Biosimilars Association

BOPA is building links with the British Biosimilars Association BBA.   The BOPA committee is keen to support our members dealing with the work of managing the introduction of biosimilars, and so is talking to the BBA about how we can work togeather can support BOPA members.  

The BBA site is worth a look as it has a good resources section that pull’s togeather a lot of key resources on biosimilars( expect to see BOPA there soon).

BOPA is also starting to work with the manufacturers of e-prescribing systems to see what can be done by the manufacturers to make their systems support the introduction of biosimilars more easily.  I’ll keep you posted as things develop, as we’ve had lots of feedback on the time people face changing their systems to ensure biosimilars are prescribed correctly, i.e. rituxumab (Mabthera) or rituxumab (Truxima) or rituximab (Rixathon) and recreasting multiple protocols, so BOPA is keen to push for key stakeholders to work togeather to make it easier.

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article